Giá Affymax Inc (AFFY)

Affymax, Inc. is a biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2006-12-15. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The firm has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.